Abstract
Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas
Highlights
Thrombocytopenia is a common occurrence in cancer patients [1,2,3,4]
This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia
In 1996 Kaye (3,4) conducted the first study of the use of recombinant human interleukin 11 in severe chemotherapy-induced thrombocytopenia who those receiving a variety of chemotherapeutic regimens for breast cancer, solid tumors and lymphomas
Summary
Thrombocytopenia is a common occurrence in cancer patients [1,2,3,4]. Albeit affecting small numbers annually, it may develop into a serious condition, causing internal bleeding, decreasing chemotherapy efficacy, and in a few cases, death [2]. Chemotherapy treatment may be reduced to insufficient levels or even delayed because of thrombocytopenia [2]. There are multiple causes of thrombocytopenia in cancer: chemotherapy-induced, immune reaction, coagulopathy, infection, drug reaction, post-transfusion purpuric thrombocytopenia. Chemotherapy is the most frequent cause [1,4]. Platelet transfusion is the primary treatment modality for chemotherapy-induced thrombocytopenia. The risks for infectious and immunologic complications increases as the number of transfusions administered [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
